Todd Michael Cooper, DO

Pronouns: He/Him/His
Todd Michael Cooper, DO

Specialties

  • Children's Title: Section Head, Oncology; Director of the Pediatric Leukemia/Lymphoma Program
  • Academic Title: Professor, Department of Pediatrics, University of Washington School of Medicine
  • Foundation Title: Evans Family Endowed Chair in Pediatric Cancer
  • Research Center: Ben Towne Center for Childhood Cancer and Blood Disorders Research
  • On Staff Since: February 2015

  • Biography

    Todd M. Cooper, DO, is an attending physician at Seattle Children's, professor of pediatrics at the University of Washington School of Medicine and the Evans Family Endowed Chair in Pediatric Cancer. Dr. Cooper is the section head of Oncology in the Cancer and Blood Disorders Center. 

    Dr. Cooper's interests and expertise focus on the development of new therapeutic strategies for the treatment of acute leukemia in children. He initially helped develop Seattle Children’s High-Risk Leukemia Program and served as co-director of the program for eight years. Prior to coming to Seattle, Dr. Cooper developed and provided leadership for phase 1 developmental therapeutics programs at the University of Alabama at Birmingham and Children's Healthcare of Atlanta/Emory University. Dr. Cooper has led phase 1 studies of new agents for relapsed acute leukemia in a variety of national consortia including the Therapeutic Advances for Childhood Leukemia Consortium, Pediatric Oncology Experimental Therapeutics Investigator Consortium and the Children's Oncology Group (COG) Consortium.

    Dr. Cooper serves as the chair of the COG Myeloid Diseases Committee and actively collaborates internationally to help maintain a cohesive strategy for the treatment of children with acute leukemia. Dr. Cooper leads COG AAML1831, a COG phase 3 study for newly diagnosed children with AML. He is the co-lead of The Leukemia & Lymphoma Society’s Pediatric Acute Leukemia (PedAL) Initiative, an international clinical trial that matches children with novel targeted therapies based on centralized next-generation genomic sequencing. These opportunities have allowed him to engage with the Food and Drug Administration and European Medical Association in discussing individual new drugs and general clinical trial designs for children with relapsed acute leukemia.

    He is intimately involved in the selection of new treatments and in designing and leading clinical trials, all with the goal of bringing positive change to the therapy of children diagnosed with AML, both nationally and internationally.

    Board Certification(s)

    Pediatric Hematology-Oncology

    Education

    Nova Southeastern University, Davie, FL

    Residency

    University of South Alabama College of Medicine, Mobile, AL

    Fellowship

    University of Texas MD Anderson Cancer Center, Houston, TX

    Research Focus Area

    Novel Therapeutics

  • Related Resources

  • Patient Testimonials

    • {{ testimonial.displayName }}
      {{ testimonial.location }}
      {{ formatTestimonialDate(testimonial.date) }}

      {{ testimonial.testimony }}

  • Awards and Honors

    Award Name Award Description Awarded By Award Date
    {{ award.name }} {{ award.description }} {{ award.organization }} {{ award.displayDate }}

  • Publications

  • Presentations

    Presentation Title Event Location Date
    {{ presentation.title }} {{ presentation.presentedAt }} {{ presentation.location }} {{ presentation.displayDate }}

  • Research Funding

    Grant Title Grantor Amount Award Date
    {{ funding.title }} {{ funding.grantedBy }} {{ funding.amount }} {{ funding.displayDate }}

  • Clinical Trials and Research Studies

    {{ item.t }}

    {{ item.st }}

    {{ item.obj }}

    Condition(s): {{ item.con }} Phase: {{ item.ph }} Clinicaltrials.gov ID: {{ item.nct }}

    No clinical trials found for Todd Michael Cooper, DO.